RIKEN Cluster for Pioneering Research Liver Cancer Prevention Research Unit, Saitama 351-0198, Japan.
Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Int J Mol Sci. 2021 Oct 28;22(21):11641. doi: 10.3390/ijms222111641.
Inhaled nebulized interferon (IFN)-α and IFN-β have been shown to be effective in the management of coronavirus disease 2019 (COVID-19). We aimed to construct a virus-free rapid detection system for high-throughput screening of IFN-like compounds that induce viral RNA degradation and suppress the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We prepared a SARS-CoV-2 subreplicon RNA expression vector which contained the SARS-CoV-2 5'-UTR, the partial sequence of ORF1a, luciferase, nucleocapsid, ORF10, and 3'-UTR under the control of the cytomegalovirus promoter. The expression vector was transfected into Calu-3 cells and treated with IFN-α and the IFNAR2 agonist CDM-3008 (RO8191) for 3 days. SARS-CoV-2 subreplicon RNA degradation was subsequently evaluated based on luciferase levels. IFN-α and CDM-3008 suppressed SARS-CoV-2 subreplicon RNA in a dose-dependent manner, with IC50 values of 193 IU/mL and 2.54 μM, respectively. HeLa cells stably expressing SARS-CoV-2 subreplicon RNA were prepared and treated with the IFN-α and pan-JAK inhibitor Pyridone 6 or siRNA-targeting ISG20. IFN-α activity was canceled with Pyridone 6. The knockdown of ISG20 partially canceled IFN-α activity. Collectively, we constructed a virus-free rapid detection system to measure SARS-CoV-2 RNA suppression. Our data suggest that the SARS-CoV-2 subreplicon RNA was degraded by IFN-α-induced ISG20 exonuclease activity.
雾化吸入干扰素(IFN)-α 和 IFN-β 已被证明可有效治疗 2019 年冠状病毒病(COVID-19)。我们旨在构建一种无病毒的高通量筛选系统,用于筛选诱导病毒 RNA 降解并抑制严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)复制的 IFN 样化合物。我们制备了一种 SARS-CoV-2 亚复制子 RNA 表达载体,该载体包含 SARS-CoV-2 5'-UTR、ORF1a 的部分序列、荧光素酶、核衣壳、ORF10 和 3'-UTR,受巨细胞病毒启动子的控制。将表达载体转染至 Calu-3 细胞,并与 IFN-α 和 IFNAR2 激动剂 CDM-3008(RO8191)一起处理 3 天。随后根据荧光素酶水平评估 SARS-CoV-2 亚复制子 RNA 的降解情况。IFN-α 和 CDM-3008 以剂量依赖性方式抑制 SARS-CoV-2 亚复制子 RNA,其 IC50 值分别为 193IU/mL 和 2.54μM。我们制备了稳定表达 SARS-CoV-2 亚复制子 RNA 的 HeLa 细胞,并对其进行了 IFN-α 和泛-JAK 抑制剂 Pyridone 6 或靶向 ISG20 的 siRNA 处理。Pyridone 6 可消除 IFN-α 的活性。ISG20 的敲低部分消除了 IFN-α 的活性。总的来说,我们构建了一种无病毒的快速检测系统来测量 SARS-CoV-2 RNA 的抑制作用。我们的数据表明,IFN-α 诱导的 ISG20 外切酶活性可降解 SARS-CoV-2 亚复制子 RNA。